These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 20619533)
1. Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Feng Z; Xu S; Liu M; Zeng YX; Kang T Cancer Lett; 2010 Nov; 297(2):190-7. PubMed ID: 20619533 [TBL] [Abstract][Full Text] [Related]
2. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells. Thompson R; Meuth M; Woll P; Zhu Y; Danson S Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433 [TBL] [Abstract][Full Text] [Related]
3. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883 [TBL] [Abstract][Full Text] [Related]
6. ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts. Gu WG; Huang Y; Yuan ZY; Peng RJ; Luo HT; He ZR; Wang SS Asian Pac J Cancer Prev; 2013; 14(3):1787-90. PubMed ID: 23679274 [TBL] [Abstract][Full Text] [Related]
7. [Radiosensitivity of nasopharyngeal carcinoma in relation to cell cycle synchronization effect of tumor necrosis factor alpha]. Yuan J; Sun N; Wang LJ; Tian W; Zhou XM; Chen DB; Gu HB Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):374-6. PubMed ID: 17425997 [TBL] [Abstract][Full Text] [Related]
8. Nigericin selectively targets cancer stem cells in nasopharyngeal carcinoma. Deng CC; Liang Y; Wu MS; Feng FT; Hu WR; Chen LZ; Feng QS; Bei JX; Zeng YX Int J Biochem Cell Biol; 2013 Sep; 45(9):1997-2006. PubMed ID: 23831840 [TBL] [Abstract][Full Text] [Related]
9. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. Xie SM; Fang WY; Liu Z; Wang SX; Li X; Liu TF; Xie WB; Yao KT J Transl Med; 2008 Oct; 6():55. PubMed ID: 18834541 [TBL] [Abstract][Full Text] [Related]
10. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925 [TBL] [Abstract][Full Text] [Related]
11. Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design. Massey AJ; Stokes S; Browne H; Foloppe N; Fiumana A; Scrace S; Fallowfield M; Bedford S; Webb P; Baker L; Christie M; Drysdale MJ; Wood M Oncotarget; 2015 Nov; 6(34):35797-812. PubMed ID: 26437226 [TBL] [Abstract][Full Text] [Related]
12. Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Low SY; Tan BS; Choo HL; Tiong KH; Khoo AS; Leong CO Cancer Lett; 2012 Jan; 314(2):166-75. PubMed ID: 22033244 [TBL] [Abstract][Full Text] [Related]
13. The preclinical study of predicting radiosensitivity in human nasopharyngeal carcinoma xenografts by 18F-ML-10 animal- PET/CT imaging. Bao X; Yang Z; Wang S; Zheng Y; Wang M; Gu B; Zhang J; Zhang Y; Zhang Y Oncotarget; 2016 Apr; 7(15):20743-52. PubMed ID: 26942701 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of CHK1 kinase by Gö6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells. Jia XZ; Yang SY; Zhou J; Li SY; Ni JH; An GS; Jia HT Biochem Pharmacol; 2009 Mar; 77(5):770-80. PubMed ID: 19059218 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Zhang JX; Qian D; Wang FW; Liao DZ; Wei JH; Tong ZT; Fu J; Huang XX; Liao YJ; Deng HX; Zeng YX; Xie D; Mai SJ Cancer Lett; 2013 Feb; 329(1):91-8. PubMed ID: 23142283 [TBL] [Abstract][Full Text] [Related]
16. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282 [TBL] [Abstract][Full Text] [Related]
17. MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Wang WJ; Wu SP; Liu JB; Shi YS; Huang X; Zhang QB; Yao KT Cancer Res; 2013 Feb; 73(3):1219-31. PubMed ID: 23269272 [TBL] [Abstract][Full Text] [Related]
18. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Qamar L; Davis R; Anwar A; Behbakht K Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells. Wang X; Masters JR; Wong YC; Lo AK; Tsao SW Anticancer Res; 2001; 21(1A):403-8. PubMed ID: 11299769 [TBL] [Abstract][Full Text] [Related]
20. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Kohn EA; Yoo CJ; Eastman A Cancer Res; 2003 Jan; 63(1):31-5. PubMed ID: 12517773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]